

October 1, 2025

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

**Company Code No. AUROPHARMA** 

To

The Corporate Relations Department

**BSE LIMITED** 

Phiroz Jeejeebhoy Towers, 25<sup>th</sup> floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir / Madam,

Sub: Update on entering into a binding agreement for transfer of shares of CuraTeQ Biologics s.r.o., by Helix Healthcare B.V., to Curateq Biologics B.V., wholly owned subsidiaries of the Company

Ref: Our letters dated July 30, 2025, August 29, 2025 and September 26, 2025

Further to the above mentioned letters dated July 30, 2025, August 29, 2025 and September 26, 2025, whereby we had informed that a binding agreement had been entered into on July 29, 2025, for transfer of the entire shares of CuraTeQ Biologics s.r.o., held by Helix Healthcare B.V., to Curateq Biologics B.V., by November 30, 2025, we would like to inform you that the share transfer has been completed and received confirmation from the local authority of Czech Republic on September 30, 2025. On confirmation of the aforesaid share transfer, CuraTeQ Biologics s.r.o., ceased to be a wholly owned subsidiary of Helix Healthcare B.V and has become a wholly owned subsidiary of Curateq Biologics B.V.

Please take the information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

**AUROBINDO PHARMA LIMITED** 

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.